X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (477) 477
Patent (39) 39
Book Chapter (27) 27
Publication (13) 13
Book / eBook (9) 9
Book Review (9) 9
Web Resource (6) 6
Conference Proceeding (3) 3
Reference (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (273) 273
rheumatology (267) 267
index medicus (177) 177
female (155) 155
male (153) 153
ankylosing spondylitis (150) 150
adult (142) 142
middle aged (112) 112
ankylosing-spondylitis (84) 84
spondylitis, ankylosing - drug therapy (82) 82
antirheumatic agents - therapeutic use (79) 79
treatment outcome (76) 76
rheumatoid-arthritis (63) 63
double-blind (59) 59
infliximab (58) 58
arthritis (56) 56
severity of illness index (55) 55
spondyloarthritis (54) 54
abridged index medicus (53) 53
inflammation (51) 51
magnetic resonance imaging (50) 50
axial spondyloarthritis (49) 49
tumor necrosis factor-alpha - antagonists & inhibitors (47) 47
antibodies, monoclonal - therapeutic use (45) 45
placebo-controlled trial (45) 45
etanercept (44) 44
diagnosis (42) 42
spondylarthritis - drug therapy (42) 42
efficacy (40) 40
patients (40) 40
care and treatment (39) 39
tumor necrosis factor-tnf (39) 39
medicine & public health (37) 37
radiography (37) 37
spondyloarthropathies (36) 36
spondylarthritis - diagnosis (35) 35
spondylitis, ankylosing - pathology (35) 35
aged (33) 33
safety (33) 33
disease progression (32) 32
double-blind method (32) 32
investigating or analysing materials by determining theirchemical or physical properties (32) 32
measuring (32) 32
physics (32) 32
radiographic progression (32) 32
spondylitis, ankylosing - diagnosis (32) 32
testing (32) 32
therapy (32) 32
back pain (31) 31
disease (31) 31
immunology (31) 31
sacroiliitis (31) 31
spondylitis, ankylosing - physiopathology (31) 31
adalimumab (30) 30
society classification criteria (30) 30
spondylarthritis (29) 29
disease-activity (28) 28
psoriatic-arthritis (28) 28
spine - pathology (28) 28
studies (28) 28
anti-inflammatory agents, non-steroidal - therapeutic use (27) 27
rheumatic diseases (27) 27
spondylitis, ankylosing - immunology (27) 27
classification (26) 26
cytokines (25) 25
sacroiliac joint - pathology (25) 25
spondylarthritis - diagnostic imaging (25) 25
inflammatory diseases (24) 24
spondylitis, ankylosing - diagnostic imaging (24) 24
tnf inhibitors (24) 24
research (23) 23
rheumatoid arthritis (23) 23
active ankylosing-spondylitis (22) 22
clinical trials (22) 22
criteria (22) 22
usage (22) 22
immunoglobulin g - therapeutic use (21) 21
prevalence (21) 21
quality of life (21) 21
receptors, tumor necrosis factor - therapeutic use (21) 21
adolescent (20) 20
animals (20) 20
time factors (20) 20
young adult (20) 20
1506 (19) 19
antirheumatic agents - adverse effects (19) 19
hla-b27 (19) 19
prognosis (19) 19
reactive arthritis (19) 19
remission induction (19) 19
tumor necrosis factor-alpha - immunology (19) 19
tumor-necrosis-factor (19) 19
drug dosages (18) 18
drug therapy (18) 18
psoriasis (18) 18
research article (18) 18
risk factors (18) 18
antibodies, monoclonal - administration & dosage (17) 17
classification criteria (17) 17
clinical-response (17) 17
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Zeitschrift fur Allgemeinmedizin, ISSN 0937-6801, 09/2011, Volume 87, Issue 9, pp. 378 - 379
Journal Article
Journal Article
BioDrugs, ISSN 1173-8804, 01/2004, Volume 18, Issue 3, pp. 206 - 206
Journal Article
Journal Article
Annals of the Rheumatic Diseases, ISSN 0003-4967, 04/2014, Volume 73, Issue 4, pp. 710 - 715
Objective Compare the radiographic progression of ankylosing spondylitis (AS) patients treated with infliximab (INF) versus historical controls (Herne cohort,... 
RADIOGRAPHIC PROGRESSION | NECROSIS-FACTOR | ASAS RECOMMENDATIONS | NONSTEROIDAL ANTIINFLAMMATORY DRUGS | INFLAMMATION | DOUBLE-BLIND | RESONANCE-IMAGING PREDICT | RHEUMATOLOGY | INFLIXIMAB | AXIAL SPONDYLOARTHRITIS | CLINICAL-RESPONSE | Single-Blind Method | Follow-Up Studies | Antirheumatic Agents - administration & dosage | Humans | Middle Aged | Antibodies, Monoclonal - therapeutic use | Male | Anti-Inflammatory Agents, Non-Steroidal - pharmacology | Infliximab | Adult | Female | Retrospective Studies | Antirheumatic Agents - pharmacology | Cervical Vertebrae - physiopathology | Lumbar Vertebrae - physiopathology | Antirheumatic Agents - therapeutic use | Cervical Vertebrae - diagnostic imaging | Drug Administration Schedule | Lumbar Vertebrae - diagnostic imaging | Antibodies, Monoclonal - pharmacology | Osteogenesis - drug effects | Spondylitis, Ankylosing - drug therapy | Treatment Outcome | Spondylitis, Ankylosing - physiopathology | Disease Progression | Spondylitis, Ankylosing - diagnostic imaging | Radiography | Anti-Inflammatory Agents, Non-Steroidal - therapeutic use | Antibodies, Monoclonal - administration & dosage | Anti-Inflammatory Agents, Non-Steroidal - administration & dosage | Observer Variation | Tumor Necrosis Factor-alpha - antagonists & inhibitors | Care and treatment | Usage | Dosage and administration | Tumor necrosis factor inhibitors | Ankylosing spondylitis | Tumor necrosis factor-TNF | Hypotheses | Inflammation | Patients | Colleges & universities
Journal Article
Lancet, The, ISSN 0140-6736, 2007, Volume 369, Issue 9570, pp. 1379 - 1390
Summary Ankylosing spondylitis is a common inflammatory rheumatic disease that affects the axial skeleton, causing characteristic inflammatory back pain, which... 
Internal Medicine | RANDOMIZED CONTROLLED TRIAL | ASAS CONSENSUS STATEMENT | MEDICINE, GENERAL & INTERNAL | TUMOR-NECROSIS-FACTOR | SHORT-TERM TREATMENT | HLA-B27 POSITIVE INDIVIDUALS | DOUBLE-BLIND | OPEN-LABEL TRIAL | PLACEBO-CONTROLLED TRIAL | RESONANCE-IMAGING EXAMINATIONS | INFLAMMATORY BACK-PAIN | Prevalence | Humans | Spondylitis, Ankylosing - drug therapy | HLA-B Antigens - immunology | Male | Spondylitis, Ankylosing - physiopathology | Radiography | Spondylitis, Ankylosing - immunology | Sacroiliac Joint - pathology | Anti-Inflammatory Agents, Non-Steroidal - therapeutic use | Treatment Failure | Adult | Female | HLA-B Antigens - adverse effects | HLA-B Antigens - genetics | Tumor Necrosis Factor-alpha - antagonists & inhibitors | Antirheumatic Agents - therapeutic use | Sacroiliac Joint - diagnostic imaging | Drug therapy | Ankylosing spondylitis | Diagnosis | Inflammatory bowel disease | Costs | Back pain | Sensitivity analysis | Chlamydia | Bowel disease | Rheumatic diseases | Bone density | Patients | Pathogenesis | Arthritis | Family medical history | Bone (axial) | Epidemiology | Market shares | Pain | Conflicts of interest | Nonsteroidal anti-inflammatory drugs | Antiinflammatory agents | Psoriasis | Cytokines | Physiotherapy | Imaging techniques | Inflammation | Disease control | Quality of life | Spondylitis | Tumor necrosis factor | Structural damage | Tumors | Structure-function relationships
Journal Article
Arthritis Research and Therapy, ISSN 1478-6354, 08/2018, Volume 20, Issue 1, pp. 191 - 10
Background: Therapeutic targeting of tumour necrosis factor (TNF)-alpha is highly effective in ankylosing spondylitis (AS) patients. However, since one-third... 
NK cells | Etanercept | CD8 | TNF-alpha blocker | Ankylosing spondylitis | Predictive biomarker | DIAGNOSIS | ACTIVATION | ANTI-TNF THERAPY | MAJOR CLINICAL-RESPONSE | RECEPTOR | RHEUMATOLOGY | ARTHRITIS | HLA-B27 | BLOCKERS | NK CELLS | CD8(+) NK cells | Tumor Necrosis Factor-alpha - metabolism | Leukocytes, Mononuclear - metabolism | Prognosis | Humans | Middle Aged | Antirheumatic Agents - immunology | Male | Spondylitis, Ankylosing - immunology | Tumor Necrosis Factor-alpha - immunology | CD8-Positive T-Lymphocytes - metabolism | Killer Cells, Natural - immunology | Adult | Female | Antirheumatic Agents - therapeutic use | Adalimumab - immunology | Leukocytes, Mononuclear - drug effects | Spondylitis, Ankylosing - drug therapy | Treatment Outcome | Spondylitis, Ankylosing - metabolism | Adalimumab - therapeutic use | CD8-Positive T-Lymphocytes - drug effects | Etanercept - immunology | Killer Cells, Natural - drug effects | Killer Cells, Natural - metabolism | CD8-Positive T-Lymphocytes - immunology | Tumor Necrosis Factor-alpha - antagonists & inhibitors | Etanercept - therapeutic use | Care and treatment | Tumor necrosis factor | Development and progression | Genetic aspects | Biological markers | Identification and classification | Health aspects | Antigens | Nuclear magnetic resonance--NMR | Psoriasis | Pathogenesis | Rheumatoid arthritis | Biomarkers | Tumor necrosis factor-TNF | TNF inhibitors | T cell receptors | CD8+ NK cells
Journal Article
Rheumatology, ISSN 1462-0324, 12/2016, Volume 55, Issue suppl 2, pp. ii38 - ii42
Journal Article
Journal Article